| Literature DB >> 9806846 |
C Lavedan1, E Leroy, R Torres, A Dehejia, A Dutra, S Buchholtz, R L Nussbaum, M H Polymeropoulos.
Abstract
The beta-synuclein protein is highly homologous to the alpha-synuclein protein for which two mutations were reported in some familial cases of Parkinson disease. It has been shown that both alpha- and beta-synucleins may be able to inhibit phospholipase D2 selectively. We have observed that the beta-synuclein gene (HGMW-approved symbol, SNCB) is highly expressed in brain including the substantia nigra, the main region of neuronal degeneration in patients with Parkinson disease. We have determined the intron-exon structure of the beta-synuclein gene and established sequencing assays that will facilitate the search for mutations in the beta-synuclein gene in patients with Parkinson disease or other neurodegenerative disorders. Copyright 1998 Academic Press.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9806846 DOI: 10.1006/geno.1998.5556
Source DB: PubMed Journal: Genomics ISSN: 0888-7543 Impact factor: 5.736